

## INSTITUTIONAL REVIEW BOARD OF THE GUTHRIE CLINIC

April 9, 2025

1) Title of study

## Application to Conduct Research Using Medical Records (that were or will be collected solely for nonresearch purposes)

Send this form to: Lori Robinson, CIC, IRB Coordinator Donald Guthrie Foundation 570-887-4885 LoriA.Robinson@guthrie.org

RB Office Use Only:	
RB Number	

This document is used to request a Waiver of Authorization to Use and Disclose Protected Health Information (PHI) and a Waiver of Consent to Participate in Research.

a Waiver of Consent to Participate in Research.					
1	Conoral Information				

2) <b>Sponsor</b> : li	nvestigator-initiated	NIH/PHS	Other (specify)	
3) Investigators	Name; Contact Inform	ation		CITI Training
Principal Investi	gator			Completed
Faculty Sponsor	*			Completed
If the Principal Inves	tigator is a resident or tra	inee of The Guthrie Clini	c, then this application r	nust be:
Sponsored by a Fa	aculty Mentor who will be	held to the same Assura	nces as the Principal In	vestigator.
<ul> <li>Accompanied by a</li> </ul>	brief protocol describing	the aims, background, p	roposed analysis, and s	ignificance of the work.
4) List of Resear	ch Team Members includ	ing Investigators and tho	se who will collect and u	se PHI
Name; Role on Study;	Contact Information			CITI Training
				Completed

# Application to Conduct Research Using Medical Records (that were or will be collected solely for nonresearch purposes)

5)	Briefly describe the purpose of the research project
6)	Approximately how many records do you expect to review?
7)	Briefly describe the time frame and search criteria for the records you propose to review (eg, hospital-acquired pneumonia, 2005-pres)
	F. 1. 2. 1. 2. 1. 2. 1. 2. 1. 2. 1. 2. 1. 2. 1. 2. 1. 2. 1. 2. 1. 2. 1. 2. 1. 2. 1. 2. 1. 2. 1. 2. 1. 2. 1. 2.
8)	Where will the review of protected health information (PHI) take place?
	Guthrie - using Guthrie approved applications (with Guthrie username and password) for data storage
	Other. Explain:
9)	Who or what institution is the legal custodian of this PHI?
-,	The Guthrie Clinic
	Other. Explain:

(that were or will be collected solely for nonresearch purposes)

10) Who will collect the PHI and who will use it?

Research Team Members Only

Other. Explain:

11) Beside the research team listed above, will PHI be disclosed to anyone else?

Yes

No

If Yes, to whom will PHI be disclosed?

12) Does the recorded data contain either a direct identifier or a link to allow the re-identification of an individual?

**Yes** No, recorded data is fully de-identified (all 18 elements of PHI are removed). If a code is used, the key to the code must not be disclosed to the researchers who are conducting research on de-identified information.

a) If "Yes" what is your plan to protect the identities from improper use and disclosure?

Any PHI will only be accessed and stored using Guthrie approved applications (with Guthrie username and password)

Other. Explain:

**b)** If "Yes", describe the plan to destroy identifiers at the earliest opportunity that is consistent with the goals of the study.

Before any results are shared, any information that could potentially identify a patient will be removed from the data

#### Other. Explain:

13)	Can this research be <i>practicably</i> conducted without access to the PHI?	Yes	No
14)	Can this research be <i>practicably</i> conducted without a waiver of consent?	Yes	No
15)	Does this protocol present any unusual risks to the confidentiality of subjects' medical information while participating or afterwards? (For example, history of drug use; genetic testing.) If yes, Explain:	Yes	No
16)	Will this protocol collect information about subjects that, if disclosed, could have adverse consequences for subjects or damage their financial standing, employability, insurability, or reputation? If yes, Explain:	Yes	No

17) Describe the type of data to be collected and used and complete the table below

# Application to Conduct Research Using Medical Records (that were or will be collected solely for nonresearch purposes)

Direct Identifiers		Indirect Identifiers
	Identifiable Information	
Used/ Collected (check if yes)		Used/ Collected (check if yes)  Disclosed (check if yes)
	Names	
	Street Address, Apartment #, Precinct, or other geocode more geographically specific than zip code	
	City/Town, State and Zip Code	
	To be considered de-identified, only the first three digits of the zip code may be used	)
	All elements of dates (except year) for dates directly related to an individual (e.g. date of birth/death, dates of admission/discharge etc.)	
	Ages less than 90 and a single aggregated category for "90 o older"	г
	Age of subject; Ages 90 or greater are not aggregated into a single category of "90 or older"	
	Telephone numbers, including fax	
	Electronic mail addresses	
	Social security numbers	
	Medical record numbers	
	Health plan beneficiary numbers or any other account number	ers
	Certificate/license numbers, & vehicle identifiers and serial nulicense plate numbers	umbers, including
	Implanted device identifiers and serial numbers	
	Web Universal Resource Locators (URLs)	
	Internet Protocol (IP) address numbers	
	Biometric identifiers, including finger and voice prints or audio	recordings
	Full face photographic images and any comparable image, in recordings	cluding video
	irect Identifiers vill be collected	None of the Indirect Identifiers noted above will be collected

(that were or will be collected solely for nonresearch purposes)

<b>Waiver of HIPAA:</b> Can this research be <i>practicably</i> conducted without a waiver of HIPAA authorization?		Yes	No	
If you are using a limited data set with no dire	ect identifiers	, a waiver of HIPAA may not be required.		
Disclosures: Do you intend to disclose information? If Yes, to whom?	Yes	No		

If yes, and the data includes only indirect identifiers as a limited data set, then a data use agreement must be signed with the recipient of the limited data set.

If yes, and the data used includes direct identifiers then the risk to privacy may be greater than minimal and full IRB review is required. Please provide rationale as to why the disclosure of the protected health information with these direct identifiers is thought to involve no more than minimal risk to the rights, welfare and/or privacy of the individuals.

Fully describe any additional privacy protections that will be put in place in order to protect the privacy of the individuals.

#### II. Assurances of Principal Investigator

#### As Principal Investigator of this study, I assure the IRB that the following statements are true:

The information provided in this form is correct. I will seek and obtain prior written approval from the IRB for any substantive modifications in the proposal, including changes in procedures, co-investigators, funding agencies, etc. I will promptly report any unexpected or otherwise significant adverse events or unanticipated problems or incidents that may occur in the course of this study. I will report in writing any significant new findings which develop during the course of this study which may affect the risks and benefits to participation. I will not begin my research until I have received written notification of final IRB approval. I will comply with all IRB requests to report on the status of the study. I will maintain records of this research according to IRB guidelines.

The PHI will not be reused or disclosed to (shared with) any other person or entity, except as required by law, for authorized oversight of the research study, or for other research for which the use or disclosure of the PHI would be permitted under the Privacy Rule. I will only store PHI on Guthrie Servers. I will not email or store PHI on portable electronic media. If these conditions are not met, I understand that approval of this research could be suspended or terminated.

Signature of Principal Investigator	Date
Signature of Faculty Sponsor	Date

(that were or will be collected solely for nonresearch purposes)

#### FOLLOWING SECTION IS TO BE COMPLETED BY IRB CHAIR OR DESIGNATED REVIEWER

III. Assessment and Determination		
WAIVER OF HIPAA Authorization – Check all that apply The following three criteria must be sati approve a waiver of authorization under the Privacy Rule:https://www.hhs.gov/hipaa/for-professionals/privacy	isfied for an IF //guidance/res	RB or Privacy Board to earch/index.html
1) The use or disclosure of protected health information involve no more than a minimathe privacy of individuals, based on, at least, the presence of the following elements:  - an adequate plan to protect the identifiers from improper use and disclosure;  - an adequate plan to destroy the identifiers at the earliest opportunity consistent with conduct or research, unless there is a health or research justification for retaining the identifiers or such rete otherwise required by law; and  - adequate written assurances that the protected health information will not be reused or disclos other person or entity, except as required by law, for authorized oversight of the research project other research for which the use or disclosure of protected health information would be permitted subpart.	of the ention is ed to any ot, or for	
2) The research could <b>not</b> practicably conducted without the waiver or alteration		
3) The research could <b>not</b> practicably conducted without access to and use of the PHI		
Waiver of HIPAA Authorization: The requirements for waiver of HIPAA authorization have been review criteria are checked, a full waiver of HIPAA authorization is determined as acceptable by the IRB as H		
WAIVER OF INFORMED CONSENT Protocol specific determinations apply due to the study design	being a seco	ndary analysis of data
1) Does the research involve more than minimal risk to the subjects?		☐ Yes ☐ No
2) Can the research be <i>practicably</i> carried out without the waiver of informed consent?	☐ Yes ☐ No	
3) Can the research be practicably carried out without using the identifiable private info in an identifiable format?	☐ Yes ☐ No	
4) Will a waiver of the requirement to obtain informed consent adversely affect the righ welfare of the subjects?	☐ Yes ☐ No	
5) Is it appropriate to provide subjects with additional pertinent information after partici	pation?	☐ Yes ☐ No
Waiver of Consent: The requirements for waiver of consent have been reviewed and criteria are answered "No" waiver of consent is determined as acceptable by the IRI		nted as above. If all
CRITERIA FOR EXPEDITED REVIEW		
(1) Does the research involve more than minimal risk to the subjects?	☐ Yes ☐	] No
(2) Does identification of the participants and/or their responses reasonably place them at risk of criminal or civil liability or be damaging to the subjects' financial standing, employability, insurability, reputation, or be stigmatizing?  If yes, will reasonable and appropriate protections be implemented so that risks related to invasion of privacy and breach of confidentiality are no greater than minimal?	Answer or	No  No (2)  No
Approved after expedited review - Category 5:		ed for Review at
Research involving materials (data, documents, records, or specimens) that have been collected, or will be collected solely for nonresearch purposes (such as medical treatment or diagnosis).	Conver	ned Meeting
Continuing Review is not required unless the reviewer explicitly justifies why continuing review would enhance protection of research subjects.[ 45CFR46.110(b)(1), 116(d), 117(c), 45CFR164.512(i)(1)] If applicable, Reviewer justification for why continuing review would enhance protection of research subjects.  Explain only as applicable:		

(that were or will be collected solely for nonresearch purposes)

Determination of FLEXIBILITY per policy GF-IRB-322-002			
$\square$ The research is determined by the IRB to be no more than minimal risk			
☐ The research is not federally funded			
☐ The research is not conducted in New York State			
All of the above are met and the research is eligible for flexibility			
OR If not all of the above are met: The research is not eligible for flexibility			
The requirements for waiver of HIPAA authorization, waiver of consent, expedited r been reviewed and documented as above.  Conflict of Interest Statement: I do not have a personal, scientific or financial intere	<u>-</u>		
Commet of interest Statement. I do not have a percentar, colonial of interest interest	l m une project.		
IRB Chair/Designated Reviewer	Date		